Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Drescher

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Gynecologic Oncology|September 2, 2008
DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinomaQinghua Feng, Georgios Deftereos, Stephen E Hawes, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 28, 2010
Activation of the MEK-S6 pathway in high-grade ovarian cancersAviva P Ventura, Sabarinath Radhakrishnan, Ann Green, et al.
Journal of Virology|January 13, 2017
Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus TherapyCharles Vragniau, Jens-Martin Hübner, Peter Beidler, et al.
Cancer Research|June 4, 2009
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenovirusesRobert Strauss, Pavel Sova, Ying Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2012
Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugsInes Beyer, Hua Cao, Jonas Persson, et al.
Journal of the National Cancer Institute|January 1, 2010
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control studyGarnet L Anderson, Martin McIntosh, Lieling Wu, et al.
Plos One|January 26, 2011
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticityRobert Strauss, Zong-Yi Li, Ying Liu, et al.
Molecular Therapy. Methods & Clinical Development|June 2, 2015
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicinMaximilian Richter, Roma Yumul, Hongjie Wang, et al.
Scientific Reports|May 13, 2022
Translational development of a tumor junction opening technologyJiho Kim, Chang Li, Hongjie Wang, et al.
Biomarker Research|August 27, 2024
A metabolite-based liquid biopsy for detection of ovarian cancerJohannes F Fahrmann, Seyyed Mahmood Ghasemi, Chae Y Han, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Gynecologic Oncology|September 2, 2008
DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinomaQinghua Feng, Georgios Deftereos, Stephen E Hawes, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 28, 2010
Activation of the MEK-S6 pathway in high-grade ovarian cancersAviva P Ventura, Sabarinath Radhakrishnan, Ann Green, et al.
Journal of Virology|January 13, 2017
Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus TherapyCharles Vragniau, Jens-Martin Hübner, Peter Beidler, et al.
Cancer Research|June 4, 2009
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenovirusesRobert Strauss, Pavel Sova, Ying Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2012
Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugsInes Beyer, Hua Cao, Jonas Persson, et al.
Journal of the National Cancer Institute|January 1, 2010
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control studyGarnet L Anderson, Martin McIntosh, Lieling Wu, et al.
Plos One|January 26, 2011
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticityRobert Strauss, Zong-Yi Li, Ying Liu, et al.
Molecular Therapy. Methods & Clinical Development|June 2, 2015
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicinMaximilian Richter, Roma Yumul, Hongjie Wang, et al.
Scientific Reports|May 13, 2022
Translational development of a tumor junction opening technologyJiho Kim, Chang Li, Hongjie Wang, et al.
Biomarker Research|August 27, 2024
A metabolite-based liquid biopsy for detection of ovarian cancerJohannes F Fahrmann, Seyyed Mahmood Ghasemi, Chae Y Han, et al.
Pageof 3